[Combination chemotherapy of advanced transitional cell carcinoma with cis-platinum, cyclophosphamide, adriamycin and 5-fluorouracil (CISCAF)]. 1984

H Fujioka, and Y Tada, and E Nakano, and M Matsuda, and M Osafune, and S Sagawa, and M Takaha, and T Sonoda

Ten patients with advanced transitional cell carcinoma were treated with the combination chemotherapy (CISCAF) consisting of cis-platinum (CDDP), cyclophosphamide (CPM), adriamycin (ADM) and 5-fluorouracil (5-FU). There were 8 males and 2 females with a median age of 57 years (range 33-76). Prior to this chemotherapy, all primary lesions were resected surgically; one patient received irradiation, one interferon. CDDP (15 mg/m2) with mannitol diuresis and ADM (7 mg/m2) were given daily for 5 days. CPM (200-300 mg/m2) was given on day one, and 5-FU (200-300 mg/m2) on day 2. Courses were repeated every 3-4 weeks for 3 courses and later every 2 months. All patients were evaluable for toxicity and 9 for response. There were 3 (33%) partial and 2 minor responses. Survival difference between responders (PR + MR) vs non-responders (NC + PD) was significant during the 30-120 days of observation, but not significant throughout the whole period (generalized Wilcoxon test). The overall toxicity due to chemotherapy was generally mild, except for one irreversible nephrotoxicity and one gastric hemorrhage treated surgically.

UI MeSH Term Description Entries
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D007682 Kidney Pelvis The flattened, funnel-shaped expansion connecting the URETER to the KIDNEY CALICES. Renal Pelvis,Pelvis, Kidney,Pelvis, Renal
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

H Fujioka, and Y Tada, and E Nakano, and M Matsuda, and M Osafune, and S Sagawa, and M Takaha, and T Sonoda
December 1986, European journal of cancer & clinical oncology,
H Fujioka, and Y Tada, and E Nakano, and M Matsuda, and M Osafune, and S Sagawa, and M Takaha, and T Sonoda
March 1980, The Medical journal of Australia,
H Fujioka, and Y Tada, and E Nakano, and M Matsuda, and M Osafune, and S Sagawa, and M Takaha, and T Sonoda
February 1981, Cancer,
H Fujioka, and Y Tada, and E Nakano, and M Matsuda, and M Osafune, and S Sagawa, and M Takaha, and T Sonoda
January 1983, Cancer chemotherapy and pharmacology,
H Fujioka, and Y Tada, and E Nakano, and M Matsuda, and M Osafune, and S Sagawa, and M Takaha, and T Sonoda
September 1984, British journal of obstetrics and gynaecology,
H Fujioka, and Y Tada, and E Nakano, and M Matsuda, and M Osafune, and S Sagawa, and M Takaha, and T Sonoda
June 1982, Clinical oncology,
H Fujioka, and Y Tada, and E Nakano, and M Matsuda, and M Osafune, and S Sagawa, and M Takaha, and T Sonoda
January 1976, The Journal of urology,
H Fujioka, and Y Tada, and E Nakano, and M Matsuda, and M Osafune, and S Sagawa, and M Takaha, and T Sonoda
July 1977, Obstetrics and gynecology,
H Fujioka, and Y Tada, and E Nakano, and M Matsuda, and M Osafune, and S Sagawa, and M Takaha, and T Sonoda
November 1976, Urology,
H Fujioka, and Y Tada, and E Nakano, and M Matsuda, and M Osafune, and S Sagawa, and M Takaha, and T Sonoda
January 1983, Cancer,
Copied contents to your clipboard!